Suppr超能文献

小儿心肌保护

Pediatric myocardial protection.

作者信息

Durandy Yves

机构信息

Institut Hospitalier Jacques Cartier, Massy, France.

出版信息

Curr Opin Cardiol. 2008 Mar;23(2):85-90. doi: 10.1097/HCO.0b013e3282f4cdb4.

Abstract

PURPOSE OF REVIEW

Myocardial protection has contributed greatly to significant advances in pediatric cardiac surgery. New refinements in perfusion techniques and cardioplegia are under evaluation. Genetic factors are also promising tools to assess and improve myocardial protection.

RECENT FINDINGS

There is increasing doubt about the efficiency of hypothermia in preventing postoperative complications. Pediatric perfusion is progressively moving towards warm perfusion, and avoiding the negative side effects of hypothermia. There is also a large body of evidence of blood cardioplegia superiority over crystalloid cardioplegia. Heat shock protein upregulation could be a relevant factor in the improvement of myocardial protection. The efficiency and safety of intermittent warm blood cardioplegia have been demonstrated in Europe in large studies. Validation of the benefit of small bypass circuit and blood-free surgery is in progress.

SUMMARY

Cardioplegia is the most important factor in myocardial protection, but all the facets of the procedure must be concerned with the protection of the heart. There is emerging evidence that warm surgery with low prime bypass and intermittent warm blood cardioplegia is a valid alternative to hypothermic perfusion with cold cardioplegia using a larger priming volume.

摘要

综述目的:心肌保护对小儿心脏手术的重大进展做出了巨大贡献。目前正在评估灌注技术和心脏停搏液的新改进。遗传因素也是评估和改善心肌保护的有前景的工具。

最新发现:对于低温预防术后并发症的有效性,人们的质疑越来越多。小儿灌注正逐渐转向温血灌注,以避免低温的负面影响。也有大量证据表明含血心脏停搏液优于晶体心脏停搏液。热休克蛋白上调可能是改善心肌保护的一个相关因素。在欧洲的大型研究中已证实间歇性温血心脏停搏液的有效性和安全性。小旁路循环和非体外循环手术益处的验证正在进行中。

总结:心脏停搏液是心肌保护中最重要的因素,但手术的所有方面都必须关注心脏的保护。新出现的证据表明,采用低预充量旁路和间歇性温血心脏停搏液的温血手术是使用较大预充量进行冷心脏停搏液低温灌注的有效替代方案。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验